This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Primary Immune Deficiency
and you are
under 75
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The purpose of this study is to assess the long-term efficacy, tolerability, and safety of IgPro20 in subjects with primary immunodeficiency (PID) as an extension to the preceding follow-up study ZLB07_001CR (NCT01458171).

Provided treatments

  • Biological: Immune globulin subcutaneous (Human)

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01461018. The sponsor of the trial is CSL Behring and it is looking for 22 volunteers for the current phase.
Official trial title:
A Multicenter Study of Long-Term Clinical Outcomes of Immune Globulin Subcutaneous (Human) (SCIG) IgPro20 in Subjects With Primary Immunodeficiency